Nifuroxazide

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DMacks (talk | contribs) at 22:46, 22 June 2020 (Remove malformatted |molecular_weight= when infobox can autocalculate it, per Wikipedia talk:WikiProject Pharmacology#Molecular weights in drugboxes (via WP:JWB)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Nifuroxazide
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral
ATC code
Identifiers
  • 4-hydroxy-N-[(E)-(5-nitrofuran-2-yl)methylideneamino]benzamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.012.293 Edit this at Wikidata
Chemical and physical data
FormulaC12H9N3O5
Molar mass275.220 g·mol−1
3D model (JSmol)
  • c1cc(O)ccc1C(=O)N/N=C/c2ccc(o2)[N+](=O)[O-]
  • InChI=1S/C12H9N3O5/c16-9-3-1-8(2-4-9)12(17)14-13-7-10-5-6-11(20-10)15(18)19/h1-7,16H,(H,14,17)/b13-7+ checkY
  • Key:YCWSUKQGVSGXJO-NTUHNPAUSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Nifuroxazide (INN) is an oral nitrofuran antibiotic, patented since 1966[1] and used to treat colitis and diarrhoea in humans and non-humans.[2] It is sold under the brand names Ambatrol, Antinal, Bacifurane, Diafuryl (Turkey), Pérabacticel (France), Antinal, Diax (Egypt), Nifrozid, Ercefuryl (Romania, Czech Republic, Russia), Erfuzide (Thailand), Endiex (Slovakia), Enterofuryl (Russia), Pentofuryl (Germany), Topron, Enterovid (Latin America), Eskapar (Mexico), Enterocolin,TERRACOLIN 100Mg./200Mg.(Bolivia), Apazid (Morocco), Nifural (Indonesia) and Septidiaryl. It is sold in capsule form and also as a suspension. A 2016 clinical trial showed Nifuroxazide to be more effective compared to probiotics in treating acute diarrhea in adults.[3]

History

Maurice Claude Ernest Carron patented the drug in the United States in 1966.[1] Subsequent patents issued to Germano Cagliero of Marxer S.p.A describe the use of nifuroxazide as an antibiotic used to treat livestock.[2]

Effectiveness in humans

In 1997, in an Ivory Coast promotional leaflet, GlaxoSmithKline claimed that nifuroxazide (under the brand name "Ambatrol") is an anti-dehydration treatment, "neutralise[s] microbacterials" in diarrhoea, and has "a spectrum which covers most enteropathogenic microbacterials, Shigella, Escherichia coli, Salmonella, Staphylococci, Klebsiella, Yersinia".[4] The international non-profit organization Healthy Skepticism, at the time using their former name, Medical Lobby for Appropriate Marketing (MaLAM), disagreed, stating "We have not found any scientific evidence to support these claims."[4] A 2016 clinical trial showed Nifuroxazide to treat diarrhea in an average of 2 days compared to 5 days with probiotics.[3]

Notes

  1. ^ a b US 3290213, Carron MC, "Antibacterial nitrofurfurylidene derivatives and methods of using same", issued 6 December 1966, assigned to Laboratories Robert et Carriere SA 
  2. ^ a b US 4093746, Cagliero G, "Method of and fodder for rearing white-meat calves for slaughter", issued 6 June 1978, assigned to Marxer SpA 
  3. ^ a b Begovic B, Ahmedtagic S, Calkic L, Vehabović M, Kovacevic SB, Catic T, Mehic M (December 2016). "Open Clinical Trial on Using Nifuroxazide Compared to Probiotics in Treating Acute Diarrhoeas in Adults". Materia Socio-Medica. 28 (6): 454–458. doi:10.5455/msm.2016.28.454-458. PMC 5239654. PMID 28144199.
  4. ^ a b "SmithKline Beecham Ambatrol (nifuroxazide)". Healthy Skepticism. June 1997. Archived from the original on 2010-12-21. Retrieved 2010-12-21.